NYSE · BIO
Bio-Rad Laboratories, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BIO: Nov 04, 2026
Bio-Rad Laboratories, Inc. Class A Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $2.61. The reported EPS for the same quarter last year was $2.26.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $2.61 | $2.61 | $2.61 | 1 |
| Dec 2026 | $2.59 | $2.59 | $2.59 | 1 |
| Mar 2027 | $2.22 | $2.22 | $2.22 | 1 |
| Jun 2027 | $2.23 | $2.23 | $2.23 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat · The Motley Fool- Zacks · Oct 6, 4:15 PM EDTNeogen (NEOG) Q1 Earnings and Revenues Beat EstimatesNeogen (NEOG) delivered earnings and revenue surprises of +60.00% and +7.07%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Sep 28, 10:03 AM EDTBiodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive TestsBDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.
- RTTNews · Sep 27, 8:23 AM EDTBiodesix Reveals Two Developing MRD Solution Collaborations With Bio-Rad And Thermo Fisher(RTTNews) – Biodesix Inc. (BDSX), a diagnostic solutions company, last week reported strategic progress for two programmes regarding Molecular Residual Disease (MRD) solutions for cancer diagnosis. Biodesix is developing the tests for tumor-informed and tumor-naive MRD using it
- MarketBeat · Sep 25, 11:02 PM EDTBio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A GrowthThe Top 3 Medical Devices Stocks to Buy NowBio-Rad Laboratories (NYSE:BIO) is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective approach to acquisiti
- Zacks · Sep 23, 10:22 AM EDTHere's Why You Should Hold Bio-Rad Stock in Your Portfolio for NowBIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
- Zacks · Sep 4, 11:30 AM EDTWhy Is Insulet (PODD) Up 8.1% Since Last Earnings Report?Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Sep 3, 11:30 AM EDTBio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Aug 21, 10:31 AM EDTIs Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
- Zacks · Aug 20, 11:23 AM EDTBio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.
- The Motley Fool · Aug 11, 8:00 PM EDTBio-Rad (BIO) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 10, 9:15 AM EDTDon't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the StockExplore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
- MarketBeat · Aug 5, 12:03 AM EDTBio-Rad Laboratories Q2 Earnings Call HighlightsThe Top 3 Medical Devices Stocks to Buy NowBio-Rad Laboratories (NYSE:BIO) reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in acad
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Bio-Rad Laboratories, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.